Acadia Pharmaceuticals Inc (NASDAQ: ACAD) flaunted slowness of -2.31% at $17.73, before settling in for the price of $18.15 at the close. Taking a more long-term approach, ACAD posted a 52-week range of $17.56-$33.99.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been 27.73% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 28.03%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 278.25%. This publicly-traded company’s shares outstanding now amounts to $164.65 million, simultaneously with a float of $163.49 million. The organization now has a market capitalization sitting at $2.92 billion. At the time of writing, stock’s 50-day Moving Average stood at $22.22, while the 200-day Moving Average is $24.96.
Acadia Pharmaceuticals Inc (ACAD) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Acadia Pharmaceuticals Inc industry. Acadia Pharmaceuticals Inc’s current insider ownership accounts for 0.78%, in contrast to 97.03% institutional ownership. According to the most recent insider trade that took place on Apr 08 ’24, this organization’s CEO sold 26,574 shares at the rate of 17.87, making the entire transaction reach 474,877 in total value, affecting insider ownership by 144,267. Preceding that transaction, on Apr 08 ’24, Company’s EVP, CHIEF FINANCIAL OFFICER sold 2,716 for 17.87, making the whole transaction’s value amount to 48,535. This particular insider is now the holder of 28,742 in total.
Acadia Pharmaceuticals Inc (ACAD) Earnings and Revenue Records
Going through the last 3-months fiscal report unveiled on the 12/30/2023, it has been observed that the corporation posted $0.28 earnings per share (EPS) during the time that was less the consensus figure (set at $0.3) by -$0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.2 per share during the current fiscal year.
Acadia Pharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 278.25% and is forecasted to reach 1.28 in the upcoming year.
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Trading Performance Indicators
Let’s observe the current performance indicators for Acadia Pharmaceuticals Inc (ACAD). It’s Quick Ratio in the last reported quarter now stands at 2.28. The Stock has managed to achieve an average true range (ATR) of 0.73. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 4.02. Similarly, its price to free cash flow for trailing twelve months is now 175.46.
In the same vein, ACAD’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.38, a figure that is expected to reach 0.06 in the next quarter, and analysts are predicting that it will be 1.28 at the market close of one year from today.
Technical Analysis of Acadia Pharmaceuticals Inc (ACAD)
Now, what If we examine the latest scores posted by [Acadia Pharmaceuticals Inc, ACAD]. During the last 5-days, its volume was lower the volume of 1.81 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 29.41% While, its Average True Range was 0.63.
Raw Stochastic average of Acadia Pharmaceuticals Inc (ACAD) in the period of the previous 100 days is set at 1.20%, which indicates a major fall in contrast to 12.46% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 24.79% that was lower than 67.11% volatility it exhibited in the past 100-days period.
